finance News

CHICAGO – Esya Labs, which is developing several ground-breaking novel research assays, today has announced that Novartis is among the first companies to use its technology. Novartis, a global healthcare company, has used a patented assay developed by Esya Labs to accelerate drug discovery efforts for Mucolipidosis Type IV, a rare inherited metabolic...
EVOTEC AND CHINOOK THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL PRECISION MEDICINES FOR CHRONIC KIDNEY DISEASES COLLABORATION WILL LEVERAGE THE NURTURE PATIENT BIOBANK AND EVOTEC’S MULTI-OMICS PLATFORMS PANHUNTER AND PANOMICS EVOTEC AND CHINOOK AIM TO CHARACTERISE MOLECULAR DRIVERS, IDENTIFY AND VALIDATE NOVEL TARGETS AND DRIVE PATIENT STRATIFICATION...
A new partnership combining AI and rare disease drug discovery with a patient-centered treatment network is seeking to unlock drug cures for the world’s most intractable diseases. AI-powered, patient-inspired technology company Healx – which is headquartered on Hills Road – has teamed up with US-based Mission: Cure, a non-profit coalition...
DEERFIELD, Ill. – Horizon Therapeutics (Nasdaq: HZNP) and the Cubs announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multiple opportunities to drive long-term growth and solidify our future as an innovation-driven biotech company,” said Tim Walbert, chairman, president and chief executive officer, Horizon....
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual global innovation challenge called The Horizon Prize focused on speeding diagnosis and care for people impacted by rare disease. Each year, The Horizon Prize will...
NEW YORK – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh...
CARLSBAD, Calif. – Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR), facilitates early diagnosis and enhances disease management of patients living with ATTR amyloidosis. The Janice Wiesman Young...